| Code | Description | Claims | Beneficiaries | Total Paid |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
16,799 |
15,353 |
$3.58M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
31,967 |
29,833 |
$2.61M |
| G0378 |
Hospital observation service, per hour |
2,840 |
1,797 |
$581K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
12,478 |
10,663 |
$546K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
4,053 |
3,507 |
$532K |
| 80053 |
Comprehensive metabolic panel |
20,459 |
16,206 |
$379K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
35,061 |
25,835 |
$370K |
| 70450 |
Computed tomography, head or brain; without contrast material |
3,178 |
2,872 |
$280K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
1,092 |
1,021 |
$275K |
| 71045 |
Radiologic examination, chest; single view |
10,032 |
8,752 |
$249K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
1,770 |
1,612 |
$246K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
5,369 |
5,002 |
$226K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
3,553 |
3,142 |
$202K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
4,911 |
4,550 |
$194K |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
3,716 |
3,507 |
$184K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
1,483 |
1,423 |
$162K |
| 83880 |
|
5,090 |
4,387 |
$144K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
2,299 |
2,255 |
$143K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
1,709 |
1,556 |
$142K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
4,105 |
3,766 |
$106K |
| 81001 |
|
15,165 |
13,720 |
$101K |
| 84484 |
|
10,273 |
6,855 |
$99K |
| 84702 |
|
4,968 |
4,427 |
$97K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
8,897 |
6,777 |
$97K |
| 84703 |
|
14,343 |
12,809 |
$95K |
| 71046 |
Radiologic examination, chest; 2 views |
2,637 |
2,459 |
$88K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
3,399 |
1,007 |
$78K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
359 |
315 |
$67K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
3,517 |
3,156 |
$67K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
1,673 |
1,559 |
$58K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
1,673 |
1,559 |
$58K |
| 83690 |
|
7,869 |
6,962 |
$58K |
| 80050 |
General health panel |
475 |
429 |
$57K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
686 |
637 |
$55K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
1,450 |
1,351 |
$50K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
967 |
828 |
$37K |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
454 |
394 |
$34K |
| 76815 |
Ultrasound, pregnant uterus, real time with image documentation, limited |
446 |
415 |
$33K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
3,798 |
3,449 |
$31K |
| 84145 |
|
1,758 |
1,489 |
$29K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
842 |
793 |
$29K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
824 |
784 |
$29K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
522 |
455 |
$25K |
| 83735 |
|
4,775 |
3,435 |
$24K |
| 86850 |
|
1,502 |
1,357 |
$23K |
| 93976 |
|
267 |
247 |
$23K |
| 80143 |
|
1,200 |
1,082 |
$22K |
| 83605 |
|
2,492 |
1,832 |
$21K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
7,831 |
6,920 |
$21K |
| 80320 |
|
1,598 |
1,409 |
$21K |
| 80179 |
|
1,187 |
1,072 |
$21K |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
1,817 |
654 |
$20K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
328 |
312 |
$19K |
| 87040 |
|
2,801 |
1,288 |
$19K |
| 94644 |
|
445 |
382 |
$19K |
| 73562 |
|
562 |
487 |
$19K |
| 82550 |
|
3,072 |
2,722 |
$18K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
3,459 |
2,490 |
$17K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
165 |
151 |
$16K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
846 |
777 |
$16K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
1,503 |
1,293 |
$15K |
| 85730 |
|
2,913 |
2,574 |
$14K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
135 |
128 |
$14K |
| 86769 |
|
445 |
390 |
$13K |
| 73030 |
|
464 |
425 |
$13K |
| 85610 |
|
3,553 |
3,008 |
$12K |
| 82803 |
|
507 |
420 |
$10K |
| 76801 |
|
117 |
104 |
$10K |
| 85379 |
|
1,285 |
1,146 |
$10K |
| 72100 |
|
222 |
219 |
$8K |
| 93971 |
|
60 |
52 |
$8K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
4,704 |
4,139 |
$8K |
| 97162 |
|
85 |
65 |
$7K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
4,043 |
3,692 |
$7K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
1,275 |
1,077 |
$7K |
| 80069 |
|
1,604 |
1,024 |
$7K |
| 87081 |
|
908 |
882 |
$7K |
| 87210 |
|
1,168 |
1,102 |
$6K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
18 |
12 |
$6K |
| 87186 |
|
1,039 |
959 |
$6K |
| J0500 |
Injection, dicyclomine hcl, up to 20 mg |
440 |
400 |
$6K |
| J0360 |
Injection, hydralazine hcl, up to 20 mg |
401 |
298 |
$6K |
| 80061 |
Lipid panel |
700 |
589 |
$5K |
| 86900 |
|
2,270 |
1,904 |
$5K |
| 86901 |
|
2,267 |
1,904 |
$5K |
| 76830 |
Ultrasound, transvaginal |
43 |
39 |
$5K |
| 82728 |
|
512 |
435 |
$5K |
| 80076 |
|
371 |
337 |
$5K |
| 72131 |
|
65 |
56 |
$5K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
4,622 |
3,056 |
$5K |
| 84100 |
|
1,737 |
1,249 |
$5K |
| 81003 |
|
2,474 |
2,273 |
$4K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
401 |
386 |
$4K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
253 |
242 |
$4K |
| 73130 |
|
78 |
74 |
$4K |
| 83721 |
|
649 |
545 |
$4K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
24 |
12 |
$4K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
2,800 |
2,507 |
$3K |
| 73630 |
|
143 |
125 |
$3K |
| 90715 |
|
188 |
183 |
$3K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
2,667 |
2,429 |
$3K |
| 70551 |
Magnetic resonance imaging, brain; without contrast material |
17 |
12 |
$2K |
| 86140 |
|
604 |
524 |
$2K |
| 87077 |
|
455 |
420 |
$2K |
| 83615 |
|
479 |
412 |
$2K |
| J1953 |
Injection, levetiracetam, 10 mg |
206 |
138 |
$2K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
2,727 |
2,511 |
$2K |
| 87088 |
|
297 |
275 |
$2K |
| J1644 |
Injection, heparin sodium, per 1000 units |
951 |
343 |
$2K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
59 |
59 |
$2K |
| 73502 |
|
26 |
25 |
$1K |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
281 |
250 |
$1K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
56 |
56 |
$1K |
| 84443 |
Thyroid stimulating hormone (TSH) |
128 |
123 |
$1K |
| J1940 |
Injection, furosemide, up to 20 mg |
737 |
280 |
$1K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,320 |
1,219 |
$1K |
| 87807 |
|
57 |
56 |
$1K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
4,619 |
3,715 |
$836.11 |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
14 |
13 |
$823.05 |
| 87340 |
|
151 |
133 |
$770.35 |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
51 |
16 |
$665.12 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
873 |
759 |
$565.48 |
| 73610 |
|
13 |
12 |
$559.76 |
| 84132 |
|
128 |
108 |
$519.27 |
| 80329 |
|
60 |
25 |
$488.52 |
| J0780 |
Injection, prochlorperazine, up to 10 mg |
183 |
172 |
$425.82 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
1,108 |
990 |
$415.15 |
| 90686 |
|
44 |
44 |
$383.49 |
| 72040 |
|
13 |
13 |
$375.68 |
| J2060 |
Injection, lorazepam, 2 mg |
598 |
461 |
$331.28 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
495 |
405 |
$273.89 |
| 84439 |
|
60 |
52 |
$250.69 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
265 |
246 |
$222.75 |
| 85018 |
|
101 |
88 |
$199.80 |
| 74022 |
|
14 |
12 |
$195.84 |
| 82962 |
|
13,407 |
3,366 |
$195.45 |
| J2919 |
Injection, methylprednisolone sodium succinate, 5 mg |
64 |
37 |
$170.38 |
| 80164 |
|
28 |
24 |
$157.62 |
| J3360 |
Injection, diazepam, up to 5 mg |
19 |
15 |
$145.70 |
| 36415 |
Collection of venous blood by venipuncture |
194 |
188 |
$140.84 |
| J8499 |
Prescription drug, oral, non chemotherapeutic, nos |
9,880 |
2,502 |
$136.33 |
| 94664 |
|
535 |
235 |
$112.77 |
| J3490 |
Unclassified drugs |
1,371 |
893 |
$103.71 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
230 |
204 |
$78.70 |
| 96376 |
|
726 |
632 |
$65.69 |
| 0353U |
|
49 |
47 |
$42.30 |
| J1630 |
Injection, haloperidol, up to 5 mg |
27 |
25 |
$15.76 |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
23 |
14 |
$14.07 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
245 |
232 |
$4.52 |
| J2470 |
Injection, pantoprazole sodium, 40 mg |
37 |
13 |
$4.43 |
| C9113 |
Injection, pantoprazole sodium, per vial |
78 |
25 |
$0.00 |
| J2704 |
Injection, propofol, 10 mg |
53 |
50 |
$0.00 |
| G0008 |
Administration of influenza virus vaccine |
26 |
26 |
$0.00 |
| C1769 |
Guide wire |
53 |
52 |
$0.00 |